• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Endosense

edit

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense’s TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

Milestones

edit

• 
  Endosense added Andrea Buscaglia as CFO.
  Posted 9/14/11 at 6:46pm
• 
  Endosense added Giovanni Leo as Co-founder and CTO.
  Posted 9/14/11 at 6:46pm
• 
  Endosense added Jan Keltjens as President and CEO.
  Posted 9/14/11 at 6:46pm
• 
  Endosense received $36M in Series B funding. (10/27/09)
  Posted 10/28/09 at 3:18am via onbiovc.com

Videos

Screenshots

edit

Above: Endosense
Uploaded: 10/28/09

Sources

1. Endosense, SA: Series B $36M (onbiovc.com) [edit]